Descripción del proyecto
Un analizador de diagnóstico integral y rentable
El diagnóstico «in vitro» es un campo amplio centrado en el análisis de variables vitales en diferentes muestras (sangre, orina, saliva) que permiten a los médicos realizar un diagnóstico. Los avances recientes en tecnología y automatización han permitido desarrollar grandes analizadores basados en estaciones de trabajo, que son capaces de analizar múltiples variables en un solo dispositivo. Con todo, estos resultan caros y los centros o clínicas de diagnóstico pequeños no pueden costearlos. Para abordar este problema, el equipo del proyecto CFA, financiado con fondos europeos, desarrolló un analizador automático, integral y rentable que permite realizar técnicas bioquímicas e inmunológicas en el mismo dispositivo. Se espera que este dispositivo mejore los servicios en un entorno local y aumente su competitividad.
Objetivo
Increasing population and rise in chronic diseases have led to an enormous demand for faster and better in-vitro diagnostic tests of parameters for improved detection and cure of diseases. However, there is significant fragmentation and separation in the IVD immunochemical analyzers market, depending on the end users’ size: on one hand there are large workstations (analyzers) capable of analyzing several parameters in one device, which are extremely large and pricey, and on the other hand, there are stand-alone devices with much narrower parameter testing, low throughput and efficiency, which are mainly based on 30 years old technology. These latter are the only option for smaller local clinics, which cannot afford the large, combined workstations, and thus, lose competitiveness to large laboratories who can afford them.
Our company, MEON Medical Solutions, is an Austrian based SME specialized in developing IVD medical devices for measurement of vital parameters to support medical professionals in clinical diagnostics. Our over 30 years of experience in the field enabled us to identify the business opportunity derived from the needs of small clinics and laboratories, for which we have developed the CFA – Clinical Flexible Analyzer- i.e. an innovative, automated, all-in-one immunochemical analyzer that combines the three most demanded diagnostic methods - Clinical Chemistry, Heterogeneous Immunoassays and Ion Selective Electrodes - in a single small modular, highly flexible and cost-efficient device. The CFA will enable small laboratories to provide an extremely cost-efficient local healthcare, and boost the growth of our company: We have estimated that after 5 years of CFA’s commercial launch in 2022, we will have engaged into 1,000 small clinics and hospitals globally, boosting the economic growth of our company, and enabling us to achieve a leading position over all other competitors.
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
8010 Graz
Austria
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.